Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring Dimension RxL clinical chemistry analyzer

Background: Monitoring whole-blood concentrations of cyclosporin A (CsA) is common practice in the management of solid organ and bone marrow transplant recipients. In a multicenter study we evaluated a new, direct (no pretreatment) CsA assay on the Dade Behring Dimension RxL(TM) system and compared results with those from the Abbott TDx CsA immunoassay and it HPLC method. Methods: Whole-blood samples from heart (n = 111; 35 patients), liver (n = 201; 44 patients), kidney (n = 279; 65 patients), and miscellaneous organ (n = 77; 12 lung, 12 bone marrow, 5 kidney/pancreas, and 1 pancreas patient) recipients were obtained from patient populations of the participating institutions. Routine clinical monitoring of CsA was performed using either the TDx method or HPLC. Results: The minimum detectable concentration of CsA averaged 9.4 mug/L, and the lower limit of quantification was 30 mug/L. The method was linear from 30 to 500 mug/L. Cross-reactivity with seven different CsA metabolites ranged from 0.0% to 5.7% for the Dimension RA assay compared with 0.4-15.9% for the TDx assay. Total imprecision (CV) averaged 6.2%, and within-run imprecision averaged 4.9%. Passing-Bablok linear regression analyses of all samples from two sites yielded the following: RA = 0.81 X TDx - 16.8; and RxL = 1.12 X HPLC - 1.7. Conclusions: The Dade Behring CsA assay for the random-access Dimension platform offers adequate performance characteristics for routine clinical use, does not require a manual pretreatment step, and demonstrates less cross-reactivity with CsA metabolites than another commonly used immunoassay. (C) 2002 American Association for Clinical Chemistry.